NEW YORK (TheStreet) -- Express Scripts (ESRX) stock was trading higher early Friday afternoon after Jefferies contended that concerns about pricing pressures from Mylan's (MYL) efforts to lower the out-of-pocket cost of its EpiPen seem "overdone."

Shares of the St. Louis-based pharmacy benefit manager fell yesterday after Mylan CEO Heather Bresch said that the company pockets just $274 of the $600 charged to customers for a two-pack of EpiPens, implying that pharmacy benefit managers "are reaping significant profits," Leerink wrote in a note.

But Jefferies claims that "runaway price inflation still comes solely from the manufacturers' side."

"We continue to believe that the [pharmacy benefit managers] enable health plan benefit sponsors to optimize costs through clinical programs, scale purchasing, and new tools/offerings such as inflation protection and cost trend guarantees, which we believe plan sponsors generally recognize," the firm added.

Separately, TheStreet Ratings team rates the stock as a "buy" with a ratings score of B.

Express Scripts' strengths such as its impressive record of earnings per share growth, compelling growth in net income, notable return on equity and reasonable valuation levels outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

You can view the full analysis from the report here: ESRX

TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author. 

Image placeholder title